Why some peptides are 'education only' here
You'll notice that some well-known peptides on this site can't be started today — they're marked education-only or waitlist. That isn't us being coy; it reflects where those peptides sit in the federal compounding review. When a peptide's eligibility for compounding is unsettled, the responsible move is to explain it honestly and let you join a waitlist rather than sell it.
We'd rather lose a sale than route you toward something that isn't on solid regulatory footing.
What PCAC actually is
The Pharmacy Compounding Advisory Committee (PCAC) is an advisory body that makes recommendations to the FDA on which bulk drug substances should be eligible for compounding under section 503A. It reviews the available data on a substance and votes on whether to recommend it for the list — the FDA then decides what to do with that recommendation.
A number of popular peptides have been on PCAC's agenda (docket FDA-2025-N-6895), which is why their status has been in flux. The committee's recommendations, and the FDA's subsequent actions, can change whether a peptide may be compounded at all.
Reclassification is not approval
This is the crucial nuance: even if a peptide's compounding status changes in a favorable direction, that is not the same as the FDA approving a drug. Being added to a list of substances eligible for compounding is a permission to compound — it is not a determination that the peptide is safe and effective for a particular use.
We'll update each peptide's profile as its status evolves, and we'll keep drawing the line between 'now compoundable' and 'FDA-approved' clearly, because they are genuinely different things.